Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO versus trilaciclib-based secondary prophylaxis for chemotherapy-induced thrombocytopenia in solid tumors
ChiCTR2600132980Phase 4Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Jul 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human thrombopoietin and trilaciclib in chemotherapy-induced thrombocytopenia (CIT) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Proportion of patients who develop grade 3 or higher thrombocytopenia. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
recombinant human thrombopoietintrilaciclib
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on ChiCTR2600132980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132980.